Monoclonal antibodies in clinical diagnosis: A brief review application

African Journal of Biotechnology

Volumn 7, Issue 8, 2008, Pages 923-925

  Saleem, Muhammad ^a   Kamal, Mustafa ^b  

^a PCSIR LABORATORIES COMPLEX   (Pakistan)

^b UNIVERSITY OF KARACHI   (Pakistan)

Author keywords

Diagnostic tool; Monoclonal antibody application

Indexed keywords

MONOCLONAL ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY PRODUCTION; ANTIGEN BINDING; BIOTECHNOLOGY; DIAGNOSTIC KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS; HERPES SIMPLEX; HUMAN; INFLUENZA; NONHUMAN; REVIEW; VIRUS INFECTION;

CHLAMYDIA; HERPES;

EID: 43449114509     PISSN: None     EISSN: 16845315     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Better M, Change CP, Robinson R, Horwitz AH (1988). Bacterial expression of a human monoclonal antibody-alkaline. Science 240: 1041-1043.
2. Bumgardner GL, Hardie I, Johnson RW, Lin A, Nashan B, Pescovitz MD, Ramos E, Vincenti F (2001). Phase III Daclizumab Study Group: Results of 3-year phase III clinical trials with daclizumabprophylaxis for prevention of acute rejection after renal transplantation. Transplantation, 15: 839-845.
3. Churchill CA, Belsey MJ (2006). Autoimmune and inflammatory disorder biolo-gics power biotech market growth through to 2010. J. Commer. Biotechnol. 12: 237-241.
4. Ekins R (1989). A shadow over immunoassay. Nature 340: 256-258.
5. Fun G (2007). Synthetic antibodies as therapeutics. Exp. Opin. Biol. Ther. 7(1): 73-87.
6. Gheradi E, Pannell R, Milstein C (1990). A single-Step procedure for cloning and selection of antibody-secreting hybridomas. J. Immunogenet, 12: 61-68.
7. Hasulo S (2000/2001). Biobusiness: Trends and Developments in Canadian Life Science, Winter. pp. 4-5. Hawkers N (2006). Patients angered as watchdog refuses to allow bowel cancer drugs on NHS. The Time, 21(8): 1-6.
8. Janis K (1996). Immunology, 2nd Edition, Pub. W.F. Freeman and Company, New York. pp. 164-167.
9. Karp G (1996). Cell and Molecular Biology. New York: John Wiley and Sons, pp. 19-24.
10. Knapp W (1989). Leucocyte typing IV white cell differentiation antigens (Oxford University Press, Oxford, pp. 140-141.
11. Koch M, Niemeyer G, Patel I, Light S, Nashan B (2002). Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation. Transplantation 73: 1640-1646.
12. Kohler G, Milstein C (1975). Continuous cultures of fused cell secreting antibodies of predefined specificity. Nature, 256: 459-497.
13. Marx U, Embleton MJ, Fischer R, Gruber FP, Hansson U, Heuer J, de Leeuw WA, Logtenberg T, Merz W, Portetelle D, Romette JL, Straughan WD (1997). Monoclonal antibody production: Thereport and recommen-dations of ECVAM Workshop 23. ATLA 25: 121-137.
14. Milstein C, Cuello AC (1983). Hybrid hybridomas and their use in immunohistochemistry. Nature 305: 537-540.
15. National Research Council (1999). A Report of the Committee on Methods of Producing Monoclonal Antibodies. Institute for Laboratory Animal Research, National Academy Press, Washington, DC. pp. 14-15.
16. Neuberger MS (1983). High pathogenic potential of low affinity antibodies. Eur. Mol. Bio. Organ. J. 2: 1373-1378.
17. Orlandi R, Gussow DH, Jones PT, Winter G (1989). Antibody engineering targeted of cancer, Recombinant. Proc. Natl. Acad. Science U.S.A, 86: 3833-3837.
18. Pijpers F, Belsey MJ (2006). Cancer remains the dominant disease target for biotech through to 2010. J. Commer. Biotechnol. 12: 294-298.
19. Pollack SJ, Jacobs JW, Schultz PG (1986). Secltive chemical catalysis by antibody. Science 234: 570-1573.
20. Stephan S, Datta K, Wang E, Li J, Brekken RA, Parangi S, Thorpe PE, Mukhopadhyay D (2004). Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin.l Cancer Res., 15: 6993-7000.
21. Ward ES, Güssow D, Griffiths AD, Jones PT, Winter G (1989). Binding activities of a repertoire of single immunoglobin variable domain secreted from E. coli. Nature 341: 544-546.